[HTML][HTML] Acute respiratory distress syndrome
MA Matthay, RL Zemans, GA Zimmerman… - Nature reviews Disease …, 2019 - nature.com
The acute respiratory distress syndrome (ARDS) is a common cause of respiratory failure in
critically ill patients and is defined by the acute onset of noncardiogenic pulmonary oedema …
critically ill patients and is defined by the acute onset of noncardiogenic pulmonary oedema …
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?
E Fan, JR Beitler, L Brochard, CS Calfee… - The Lancet …, 2020 - thelancet.com
The COVID-19 pandemic has seen a surge of patients with acute respiratory distress
syndrome (ARDS) in intensive care units across the globe. As experience of managing …
syndrome (ARDS) in intensive care units across the globe. As experience of managing …
Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials
CS Calfee, K Delucchi, PE Parsons… - The Lancet …, 2014 - thelancet.com
Background Subphenotypes have been identified within heterogeneous diseases such as
asthma and breast cancer, with important therapeutic implications. We assessed whether …
asthma and breast cancer, with important therapeutic implications. We assessed whether …
A living WHO guideline on drugs for covid-19
This living guideline by Arnav Agarwal and colleagues (BMJ 2020; 370: m3379, doi:
10.1136/bmj. m3379) was last updated on 22 April 2022, but the infographic contained two …
10.1136/bmj. m3379) was last updated on 22 April 2022, but the infographic contained two …
Is a “cytokine storm” relevant to COVID-19?
P Sinha, MA Matthay, CS Calfee - JAMA internal medicine, 2020 - jamanetwork.com
In its most severe form, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …
virus that causes coronavirus disease 2019 (COVID-19), leads to a life-threatening …
Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
JG Wilson, KD Liu, H Zhuo, L Caballero… - The Lancet …, 2015 - thelancet.com
Background No effective pharmacotherapy for acute respiratory distress syndrome (ARDS)
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …
Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy
KR Famous, K Delucchi, LB Ware… - American journal of …, 2017 - atsjournals.org
Rationale: We previously identified two acute respiratory distress syndrome (ARDS)
subphenotypes in two separate randomized controlled trials with differential response to …
subphenotypes in two separate randomized controlled trials with differential response to …
[HTML][HTML] Redefining critical illness
Research and practice in critical care medicine have long been defined by syndromes,
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …
A living WHO guideline on drugs for covid-19
Updates This is the thirteenth version (twelfth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …
earlier versions (available as data supplements). New recommendations will be published …